Your Article Summary
See Latest ArticlesRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in type 2 diabetes pts is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Data are inconclusive for effects on myocardial infarction; howver, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality vs standard glucose-lowering drugs.
Methods- Study of cardiovascular outcomes after rosiglitazone addition to either metformin or sulfonylurea vs combination of the 2 over 5-7-yr follow-up
- Comparative safety assessment
- Multi-center, open-label trial of 4447 type 2 diabetes pts on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
- Randomization to addition of rosiglitazone (2220 pts) or combination of metformin and sulfonylurea (active control group, 2227)
- Primary endpoint: cardiovascular hospitalization or cardiovascular death
- During mean 5.5-yr follow-up, primary outcome met by 321 rosiglitazone pts and 323 active controls, meeting non-inferiority criterion
- Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
- Upper and distal lower limb fracture rates increased mainly in female rosiglitazone pts
- Mean HbA1c lower in rosiglitazone vs control group at 5 yrs
Related Articles
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09
Relevance Score: 88%
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09
Relevance Score: 87%
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 87%
Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09
Relevance Score: 85%
Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09
Relevance Score: 85%
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Foam sclerotherapy: cardiac and cerebral monitoring
Phlebology, 12/04/09
Comparison of Antero-Lateral Versus Antero-Posterior Electrode Position for Biphasic External Cardioversion of Atrial Flutter
The American Journal of Cardiology, 12/04/09
Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
Cleveland Clinic Journal of Medicine, 12/04/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rifaximin in the management of colonic diverticular disease
Expert Review of Gastroenterology & Hepatology, 12/06/09
Divalproex Sodium-Induced Eosinophilic Pleural Effusion
American Journal of Therapeutics, 12/04/09
Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Muscular Strength Is Inversely Related to Prevalence and Incidence of Obesity in Adult Men
Obesity, 12/04/09
Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09
Selenium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09